News | April 25, 2025
We’re working at full force to put Bayer back on a profitable growth path: Bill Anderson, CEO, Bayer
Bayer expects 2025 to be the most difficult year of its turnaround
Bayer expects 2025 to be the most difficult year of its turnaround
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
EBITDA before special items decreases to €4.08 billion (7.4%)
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
EBITDA before special items falls 1.3 percent to € 4.41 billion
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Juergen Eckhardt joined Bayer in 2016 to help start Leaps by Bayer
Subscribe To Our Newsletter & Stay Updated
